Dr. Ueffing did his PhD at Columbia University and received his doctorate (rer. nat.) from the University of Freiburg (1991) for his work on the biochemistry and cell signaling of Protein Kinase C. With a previous background as a group leader in pharmaceutical industry (Goedeke-Parke-Davis) as well as an affiliation with a University Medical Centre, he has focused on neurodegeneration in midbrain and retina with specific focus on human mutations, the molecular mechanisms of disease and therapy development. Starting work on LRRK2 by 2004, his group was among the first to describe its kinase activity (2006), MKKs as a group of substrates within the MAPK signaling network (2009), and the purification of the human active kinase as well as (auto-) phosporylation (2010). Several large scale and/or targeted projects on the national (www.ngfn.de/en/parkinson.html) and the EU level most importantly, “Interaction Proteome“ (www.interaction-proteome.org), NeuroTrain (www.neurotrain.org) and “Proteome Binders” (www.proteomebinders.org) have contributed to a solid expertise on the biochemical, structural and physiological properties of LRRK2. Marius is coordinator of several national and European research consortia, member of the Board of Directors of HUPO (www.hupo.org) and the current President of the German Society for Proteome Research (www.dgpf.org).